Exicure has added an $11.2m private placement led by Luye Pharma to the $20.1m it raised from investors including AbbVie last month.

Pharmaceutical company Luye Pharma led an $11.2m extension yesterday to a funding round being raised by US-based gene regulating drug developer Exicure that now stands at $31.3m.

The capital was provided through a private placement that also included venture capital firm Knoll Capital Management, Eager Info Investments and Purple Arch Ventures, a VC fund backed by alumni of Northwestern University, from which Exicure was spun out.

Katalyst Securities and private investor Mark Tompkins co-led the $20.1m first tranche of the…